{"ResultsReport": {"xmlns": "http://integration.foundationmedicine.com/reporting", "xmlnsxsi": "http://www.w3.org/2001/XMLSchema_instance", "xsischemaLocation": "http://integration.foundationmedicine.com/reporting http://integration.foundationmedicine.com/reporting/ResultsReport.2.1.xsd", "CustomerInformation": {"ReferenceID": "01_2022_00024064", "CSN": null, "TRF": "ORD_1479431_01", "MRN": "48605965", "PhysicianId": "109266", "NPI": "International"}, "ResultsPayload": {"FinalReport": {"xmlnsxsd": "http://www.w3.org/2001/XMLSchema", "StagingId": "1211448", "clinicalId": "1212818", "xsinoNamespaceSchemaLocation": "http://integration.foundationmedicine.com/reporting/ClinicalReport.1.1.xsd", "Application": {"ApplicationSettings": {"ApplicationSetting": {"Name": "Statement", "Value": null}}}, "DemographicCorrectionDate": null, "ReportId": "ORD_1479431_01", "SampleName": "US1418085.01", "Version": "0", "Sample": {"FM_Id": "ORD_1479431_01", "SampleId": "US1418085.01", "BlockId": "S111-77378C", "TRFNumber": "ORD_1479431_01", "TestType": "FoundationOne CDx             ", "SpecFormat": "FFPE", "ReceivedDate": "2022_10_17", "processSites": {"processSite": [{"address": "150 Second St., 1st Floor, Cambridge, MA 02141", "cliaNumber": "22D2027531", "locationID": "1", "locationName": "Cambridge", "processID": "1", "processName": "Extracted DNA"}, {"address": "150 Second St., 1st Floor, Cambridge, MA 02141", "cliaNumber": "22D2027531", "locationID": "1", "locationName": "Cambridge", "processID": "1", "processName": "LC"}]}, "TumorPurity": "30", "SpecimenLocation": "nan"}, "PMI": {"ReportId": "S111-97956", "MRN": "48605965", "FullName": "\u738b\u4e9c\u81fb", "FirstName": "Ya Chen", "LastName": "Wang", "SubmittedDiagnosis": "Adenocarcinoma, Lung", "Gender": "Female", "DOB": "1965_11_01", "OrderingMD": "\u9127\u8c6a\u5049", "OrderingMDId": "109266", "Pathologist": "\u9673\u5fd7\u5b78", "CopiedPhysician1": null, "MedFacilName": "Taipei Veterans General Hospital", "MedFacilID": "205872", "SpecSite": "Lung", "CollDate": "2022_08_31", "ReceivedDate": "2022-10-29 00:00:00", "CountryOfOrigin": "TW", "TumorType": "Lung Adenocarcinoma"}, "PertinentNegatives": {"PertinentNegative": [{"Gene": "ALK"}, {"Gene": "EGFR"}, {"Gene": "ERBB2"}, {"Gene": "KRAS"}, {"Gene": "MET"}, {"Gene": "RET"}, {"Gene": "ROS1"}]}, "Summaries": {"alterationCount": "11", "clinicalTrialCount": "10", "resistiveCount": "0", "sensitizingCount": "5"}, "VariantProperties": {"VariantProperty": [{"geneName": "BRD4", "isVUS": "true", "variantName": "P1012L"}, {"geneName": "CIC", "isVUS": "true", "variantName": "I155V"}, {"geneName": "IRS2", "isVUS": "true", "variantName": "G1308V"}, {"geneName": "MKNK1", "isVUS": "true", "variantName": "R35Q"}, {"geneName": "MST1R", "isVUS": "true", "variantName": "D507V"}, {"geneName": "SPEN", "isVUS": "true", "variantName": "T796S"}, {"geneName": "STAG2", "isVUS": "true", "variantName": "S823Y"}]}, "priorTests": null, "Genes": {"Gene": [{"Name": "BRAF", "Include": "true", "Alterations": {"Alteration": {"Name": "V600E", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "V600E"}}, "Interpretation": "BRAF encodes a member of the RAF family of protein kinases, which includes ARAF, BRAF, and CRAF. These kinases function downstream of RAS as part of the MAPK (RAF_MEK_ERK) signaling cascade that facilitates cell proliferation, survival and transformation (Holderfield et al., 2014; 24957944, Burotto et al., 2014; 24948110). BRAF mutations have been reported in up to 20% of all cancers, with the majority of mutations occurring at the V600 position (Davies et al., 2002; 12068308, Kandoth et al., 2013; 24132290). Among the V600 mutations, V600E accounts for 70_80% of observations, V600K for 10_30%, and V600R for 5_7%, with V600D comprising the majority of the rest (Davies et al., 2002; 12068308, Greaves et al., 2013; 23273605, Klein et al., 2013; 23237741). Mutations at V600 are Class 1 BRAF alterations that have been shown to constitutively activate BRAF kinase and hyperactivate the downstream MEK_ERK signaling, promoting oncogenic transformation (Wellbrock et al., 2004; 15059882, Davies et al., 2002; 12068308). In multiple cancer types, multiple mutations at V600, including V600E, V600K, V600R, V600D, and V600M, exhibited sensitivity to V600_targeted therapies (Hauschild et al., 2012; 22735384, McArthur et al., 2014; 24508103, Fisher et al., 2012; 22904646, Yang et al., 2010; 20551065, Gentilcore et al., 2013; 23317446, Klein et al., 2013; 23237741, van den Brom et al., 2013; 23473613, Klein et al., 2013; 23490649, Ponti et al., 2013; 23463675, Ponti et al., 2012; 23031422, Parakh et al., 2015; 25382067, Lee et al., 2017; 28194436); other mutations at this position are predicted to behave similarly. BRAF mutations have been reported in up to 4% of non_small cell lung cancer (NSCLC) cases in various studies (An et al., 2013; ASCO Abstract 8101) (Paik et al., 2011; 21483012, Brustugun et al., 2014; 24552757, Carneiro et al., 2014; 24594201, Li et al., 2014; 24743704), with a large_scale meta_analysis suggesting a frequency of 3% (Chen et al., 2014; 24979348). BRAF mutations are significantly more prevalent in lung adenocarcinoma than non_adenocarcinoma NSCLC (Brustugun et al., 2014; 24552757, Chen et al., 2014; 24979348). BRAF mutations can co_occur with alterations in other known oncogenic drivers of NSCLC, including EGFR, KRAS, and ALK (An et al., 2013; ASCO Abstract 8101, Brustugun et al., 2014; 24552757, Li et al., 2014; 24743704). Although one retrospective study in Europe observed shorter OS for patients with BRAF_mutated metastatic or recurrent NSCLC (HR=1.38 compared with patients with KRAS mutations or no drivers)(Wiesweg et al., 2021; 33872981), other studies did not detect a prognostic effect of BRAF mutations overall (Couraud et al., 2019; 31181537, Chen et al., 2014; 24979348, An et al., 2013; ASCO Abstract 8101). Comparing survival for patients with different BRAF mutation classes (I_III), retrospective studies reported similar OS between classes on non_targeted treatments (Dagogo_Jack et al., 2019; 30224342, Lin et al., 2019; 31470866, Wiesweg et al., 2021; 33872981). Patients with BRAF_mutated metastatic NSCLC may benefit from PD_1/L1 immune checkpoint inhibitors (ORR of 24_29% [9/37_4/14]) (Mazieres et al., 2019; 31125062, Wiesweg et al., 2021; 33872981), irrespective of the BRAF mutation class (Sakai et al., 2020; ASCO Abstract 9590). Patients with BRAF V600E_mutated metastatic non_small cell lung cancer achieved clinical benefit from the combination of the BRAF V600 inhibitor dabrafenib and MEK inhibitor trametinib. In the first_line setting, patients achieved an ORR of 64% (23/36), a median PFS (mPFS) of 10.9 months, and a median OS (mOS) of 24.6 months (Planchard et al., 2017; 28919011). Patients with previously treated metastatic disease achieved an ORR of 67% (38/57), an mPFS of 10.2 months, and an mOS of 18.2 months (Planchard et al., 2016; 27283860, Planchard et al., 2017; ASCO Abstract 9075). The BRAF V600 inhibitors vemurafenib and dabrafenib have also demonstrated efficacy as monotherapies for patients with BRAF V600E_mutated non_small cell lung cancer (Mazieres et al., 2020; 31959346, Subbiah et al., 2019; DOI: 10.1200/PO.18.00266, Subbiah et al., 2020; 32029534, Hainsworth et al., 2018; 29320312, Planchard et al., 2016; 27080216). The ERK1/2 kinase inhibitor ulixertinib was evaluated for patients with BRAF_mutated lung cancer; 3 out of 12 patients achieved a PR, including 2 responses for patients with BRAF V600E mutations (Sullivan et al., 2018; 29247021). In 2 Phase 1 studies evaluating the MEK_pan_RAF dual inhibitor CH5126766, 3 patients harboring BRAF V600E mutations experienced PRs, including 2 patients with melanoma (Martinez_Garcia et al., 2012; 22761467) and 1 patient with low_grade serous ovarian carcinoma (Guo et al., 2020; 33128873).", "Include": "true", "ClinicalTrialNote": "BRAF V600 mutation may predict sensitivity to inhibitors of BRAF, MEK, or ERK. BRAF activating alterations may predict sensitivity to inhibitors of BRAF, MEK, or ERK. Limited clinical and preclinical studies indicate BRAF mutations may predict sensitivity to MEK_pan_RAF dual inhibitors.", "Therapies": {"Therapy": [{"Name": null, "GenericName": "Encorafenib + Binimetinib", "FDAApproved": "false", "Rationale": "<p><b>Approved Indications:</b> The combination of the BRAF inhibitor encorafenib and MEK inhibitor binimetinib is FDA approved to treat patients with melanoma with BRAF V600E or BRAF V600K mutations. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of clinical efficacy in the treatment of patients with BRAF V600_mutated melanoma (Dummer et al., 2018; 29573941, Ascierto et al., 2020; 31901705, Holbrook et al., 2020; 31658370, Sullivan et al., 2020; 32669376), and activity in colorectal, thyroid, and lung cancer (Sullivan et al., 2020; 32669376, Kefford et al., 2013; Melanoma Bridge Meeting Abstract P5, McLoughlin et al., 2019; 31757377), activating alterations affecting BRAF predict sensitivity to the combination of encorafenib and binimetinib. </p> <p><b>Supporting Data:</b> A case study observed improved responses in leptomeningeal and brain metastases for a patient with BRAF V600E_mutated lung adenocarcinoma following combination treatment with encorafenib and binimetinib (McLoughlin et al., 2019; 31757377). The combination of encorafenib and binimetinib has been reported to provide clinical benefit for patients with various solid tumors harboring BRAF V600 activating alterations (Dummer et al., 2018; 29573941, Sullivan et al., 2020; 32669376, Kefford et al., 2013; Melanoma Bridge Meeting Abstract P5, McLoughlin et al., 2019; 31757377), and has been studied primarily in the context of BRAF V600_mutated melanoma where patients treated with this combination achieved greater PFS and OS compared with encorafenib or vemurafenib monotherapy (Dummer et al., 2018; 29573941, Ascierto et al., 2020; 31901705, Gogas et al., 2020; ASCO Abstract 10012). A combination of encorafenib, binimetinib, and the CDK4/6 inhibitor ribociclib in a Phase 1b trial for patients with BRAF V600_mutant cancers elicited responses in melanoma, astrocytoma, unknown carcinoma, and in 1 of 3 patients with colorectal cancer; a Phase 2 study of this combination in V600_mutant melanoma reported an ORR of 52.4% (22/42), including 5 CRs, median PFS of 9.2 months, and median OS of 19.4 months (Ascierto et al., 2017; ASCO Abstract 9518). </p>", "ApprovedUses": null, "Effect": "Sensitizing", "Include": "true", "IncludeInSummary": "true", "ReferenceLinks": null}, {"Name": null, "GenericName": "Dabrafenib +\u00a0Trametinib", "FDAApproved": "true", "Rationale": "<p><b>Approved Indications:</b> Dabrafenib is a BRAF V600 selective inhibitor and trametinib is a MEK inhibitor. These 2 therapies are FDA approved in combination to treat metastatic non_small cell lung cancer (NSCLC) with BRAF V600E mutation, advanced anaplastic thyroid cancer (ATC) with BRAF V600E mutation, and advanced solid tumors with BRAF V600E mutation in adult and pediatric patients 6 years of age and older. This combination is also approved to treat patients with melanoma with BRAF V600E/K mutations. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of clinical evidence in various solid tumors and hematologic malignancies, BRAF activating alterations may confer sensitivity to the combination of BRAF V600_targeted therapies and MEK inhibitors such as dabrafenib and trametinib (Long et al., 2017; 28475671, Long et al., 2015; 26037941, Robert et al., 2015; 25399551, Planchard et al., 2017; 28919011, Subbiah et al., 2018; 29072975, Corcoran et al., 2015; 26392102, Kreitman et al., 2018; ASH Abstract 391, Lagana et al., 2018; DOI: 10.1200/PO.18.00019, Salama et al., 2020; 32758030, Hendifar et al., 2021; 34476331, Wen et al., 2021; 34838156, Subbiah et al., 2020; 32818466). </p> <p><b>Supporting Data:</b> In a Phase 2 trial for patients with previously treated BRAF V600E_mutated metastatic non_small cell lung cancer (mNSCLC), dabrafenib in combination with trametinib achieved an ORR of 68% (39/57), median PFS (mPFS) of 10.2 months, median OS (mOS) of 18.2 months, and 5_year survival rate of 19% (Planchard et al., 2022; 34455067); dabrafenib plus trametinib demonstrated similar activity as first_line therapy for patients with BRAF V600E_mutated mNSCLC, with an ORR of 64% (23/36), mPFS of 10.8 months, mOS of 17.3 months, and 5_year survival rate of 22% (Planchard et al., 2017; 28919011, Planchard et al., 2022; 34455067). In one retrospective study, 40 patients with BRAF V600E_mutated NSCLC treated with dabrafenib plus trametinib achieved a mPFS of 17.5 months and mOS of 25.5 months (Auliac et al., 2020; 33276639), whereas in another, 100% (9/9, including 5 newly diagnosed) of patients with BRAF_mutated NSCLC achieved disease control and 6_month mPFS on dabrafenib plus trametinib (Mu et al., 2020; 32411601). Multiple case studies have also reported clinical benefit for patients with NSCLC harboring either a BRAF V600E mutation (Kashizaki et al., 2021; 33278771, Dotsu et al., 2021; 33215864, Adachi et al., 2020; 32093631, Shimada et al., 2021; 34023984, Pan, 2019; 31250402, Li et al., 2021; 34516041, Ota et al., 2021; 34484797, Yamamoto et al., 2019; 31027751, Pervere et al., 2017; 28024926, Kim et al., 2019; 31440061, Tsakonas et al., 2020; 32522509) or a non_V600E mutation (Su et al., 2021; 34590045, Dagogo_Jack, 2020; 32981611, Liu et al., 2020; 32553555) following treatment with dabrafenib plus trametinib. Dabrafenib can induce adverse effects such as the development of cutaneous squamous cell carcinomas and keratoacanthomas caused by inactivation of wildtype BRAF that leads to paradoxical activation of the MAPK pathway, but it has been reported to be well tolerated in patients with BRAF V600E_mutated thyroid cancer (Gibney et al., 2013; 23712190, Hauschild et al., 2012; 22735384, Falchook et al., 2015; 25285888). Patients with melanoma harboring BRAF V600E or V600K mutation treated with a combination of dabrafenib and trametinib experienced significantly lower rates of cutaneous squamous cell carcinoma and regression of established BRAF inhibitor_induced skin lesions (Flaherty et al., 2012; 23020132, Long et al., 2014; 25265492, Peters et al., 2014; 25185693, Long et al., 2015; 26037941, Roberts et al., 2015; 25399551). </p>", "ApprovedUses": null, "Effect": "Sensitizing", "Include": "true", "IncludeInSummary": "true", "ReferenceLinks": null}, {"Name": null, "GenericName": "Vemurafenib", "FDAApproved": "false", "Rationale": "<p><b>Approved Indications:</b> Vemurafenib is a selective inhibitor of BRAF with V600 mutations and is FDA approved to treat melanoma as monotherapy for patients with the BRAF V600E mutation. It is also approved to treat patients with Erdheim_Chester Disease (ECD) with BRAF V600 mutation. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of strong clinical data, BRAF V600E mutations may confer sensitivity to V600_targeted therapies such as vemurafenib (Chapman et al., 2011; 21639808, McArthur et al., 2014; 24508103, Fisher et al., 2012; 22904646, Ponti et al., 2013; 23463675, Kurzrock et al., 2020; 32067683, Hyman et al., 2015; 26287849, Subbiah et al., 2020; 32029534, Mazieres et al., 2020; 31959346, Larkin et al., 2019; 30580112, Kaley et al., 2018; 30351999). </p> <p><b>Supporting Data:</b> Dabrafenib and vemurafenib have primarily been studied in the context of BRAF V600E_positive melanoma and NSCLC (Hauschild et al., 2012; 22735384, McArthur et al., 2014; 24508103, Fisher et al., 2012; 22904646, Yang et al., 2010; 20551065, Gentilcore et al., 2013; 23317446, Klein et al., 2013; 23237741, van den Brom et al., 2013; 23473613, Klein et al., 2013; 23490649, Ponti et al., 2013; 23463675, Ponti et al., 2012; 23031422, Parakh et al., 2015; 25382067, Klempner et al., 2016; 27048246). Single_agent vemurafenib has been examined in Phase 2 basket trials including cohorts with BRAF_mutated NSCLC. In the VE_BASKET study for patients with BRAF V600 mutation, vemurafenib elicited an ORR of 37% (23/62 PRs), a median PFS of 6.5 months, a median OS of 15.4 months, and a median response duration of 7.2 months in the overall NSCLC cohort; similar ORRs were achieved by treatment_na\u00efve and previously_treated patients (Subbiah et al., 2019; DOI: 10.1200/PO.18.00266, Subbiah et al., 2020; 32029534). In the AcS\u00e9 study, patients with BRAF V600_mutated NSCLC and progression on 1 or more standard treatments achieved an ORR of 44.8% (43/96), with a median PFS, OS, and duration of response of 5.2, 10, and 6.4 months, respectively; patients with BRAF non_V600 mutations did not experience a response (0/15) and achieved a median PFS of 1.8 months and a median OS of 5.2 months (Mazieres et al., 2020; 31959346). Similarly, in the MyPathway study, patients with advanced BRAF V600E_mutated NSCLC experienced an ORR of 43% (6/14, 1 CR), while the response rate was low for diverse tumor types with BRAF non_V600 mutation (4%, 1/23) (Hainsworth et al., 2018; 29320312). A retrospective study reported an ORR of 54% (13/24, 2 CR) and a DCR of 96% (23/24) for patients with V600E_mutated advanced NSCLC treated with vemurafenib following prior BRAF inhibitor therapy (Gautschi et al., 2015; 26200454). Case reports support the activity of vemurafenib against BRAF V600E_mutated metastatic NSCLC (Peters et al., 2013; 23733758, Liu et al., 2018; 30214735), including patients with intracranial disease (Robinson et al., 2014; 24888229) or pulmonary sarcomatoid carcinoma (Schrock et al., 2017; 28315738). One patient with NSCLC, low TMB, and TRIM24_BRAF fusion experienced a PR with vemurafenib treatment (Lai et al., 2018; ASCO Abstract e13537). Vemurafenib can induce adverse effects, such as the development of cutaneous squamous cell carcinomas, keratoacanthomas, and new primary melanomas caused by inactivation of wildtype BRAF and leading to paradoxical activation of the MAPK pathway (Gibney et al., 2013; 23712190, McArthur et al., 2014; 24508103). In a Phase 1b trial, patients with BRAF V600E_mutated melanoma treated with a combination of vemurafenib and cobimetinib had increased RR (87%) and PFS (13.7 months) compared to the RR and PFS values previously reported for vemurafenib or MEK inhibitor monotherapy; this combination also resulted in lower rates of cutaneous SCC (Ribas et al., 2014; 25037139). </p>", "ApprovedUses": null, "Effect": "Sensitizing", "Include": "true", "IncludeInSummary": "true", "ReferenceLinks": null}, {"Name": null, "GenericName": "Dabrafenib", "FDAApproved": "false", "Rationale": "<p><b>Approved Indications:</b> Dabrafenib is a BRAF V600_selective inhibitor that is FDA approved as a monotherapy to treat melanoma with BRAF V600E or V600K mutations. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> Mutations at BRAF V600, including V600E, V600K, V600R, V600D, and V600M, have been reported to exhibit clinical sensitivity to V600_targeted therapies (Hauschild et al., 2012; 22735384, McArthur et al., 2014; 24508103, Fisher et al., 2012; 22904646, Yang et al., 2010; 20551065, Gentilcore et al., 2013; 23317446, Klein et al., 2013; 23237741, van den Brom et al., 2013; 23473613, Klein et al., 2013; 23490649, Ponti et al., 2013; 23463675, Ponti et al., 2012; 23031422, Parakh et al., 2015; 25382067, Klempner et al., 2016; 27048246); therefore, this tumor may be sensitive to V600_targeted therapy such as dabrafenib. </p> <p><b>Supporting Data:</b> In a Phase 2 trial for BRAF V600E_mutated metastatic non_small cell lung cancer (NSCLC), dabrafenib monotherapy resulted in PRs for 33% (26/78) and disease control for 58% (45/78) of previously treated patients; 4/6 treatment_naive patients achieved PRs (Planchard et al., 2016; 27080216). The median PFS and OS were 5.5 months and 12.7 months, respectively (Planchard et al., 2016; 27080216). Similar median PFS (5.0 months) and OS (10.8 months) were reported in a retrospective study of BRAF_targeted therapy outcomes for BRAF_mutated metastatic NSCLC; 44% (4/9) of patients responded to dabrafenib in this study (Gautschi et al., 2015; 26200454). A patient with BRAF V600E_mutated lung adenocarcinoma experienced a PR to dabrafenib of 8 months and subsequently had progressive disease that coincided with the acquisition of a secondary KRAS mutation (Rudin et al., 2013; 23524406). Dabrafenib and vemurafenib have primarily been studied in the context of BRAF V600E_positive melanoma and NSCLC (Hauschild et al., 2012; 22735384, McArthur et al., 2014; 24508103, Fisher et al., 2012; 22904646, Yang et al., 2010; 20551065, Gentilcore et al., 2013; 23317446, Klein et al., 2013; 23237741, van den Brom et al., 2013; 23473613, Klein et al., 2013; 23490649, Ponti et al., 2013; 23463675, Ponti et al., 2012; 23031422, Parakh et al., 2015; 25382067, Klempner et al., 2016; 27048246). Dabrafenib can induce adverse effects such as the development of cutaneous squamous cell carcinomas and keratoacanthomas caused by inactivation of wildtype BRAF that leads to paradoxical activation of the MAPK pathway, but it has been reported to be well tolerated in patients with BRAF V600E_mutated thyroid cancer (Gibney et al., 2013; 23712190, Hauschild et al., 2012; 22735384, Falchook et al., 2015; 25285888). Patients with melanoma harboring BRAF V600E or V600K mutation treated with a combination of dabrafenib and trametinib experienced significantly lower rates of cutaneous squamous cell carcinoma and regression of established BRAF inhibitor_induced skin lesions (Flaherty et al., 2012; 23020132, Long et al., 2014; 25265492, Peters et al., 2014; 25185693, Long et al., 2015; 26037941, Roberts et al., 2015; 25399551). </p>", "ApprovedUses": null, "Effect": "Sensitizing", "Include": "true", "IncludeInSummary": "true", "ReferenceLinks": null}, {"Name": null, "GenericName": "Vemurafenib + Cobimetinib", "FDAApproved": "false", "Rationale": "<p><b>Approved Indications:</b> Vemurafenib is a selective inhibitor of BRAF with V600 mutations and cobimetinib is a MEK inhibitor. The combination is FDA approved to treat patients with melanoma with BRAF V600E or V600K mutations. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of clinical evidence in melanoma and colorectal carcinoma, BRAF activating alterations may confer sensitivity to the combination of BRAF V600_targeted therapies and MEK inhibitors such as vemurafenib and cobimetinib (Ascierto et al., 2016; 27480103, Ribas et al., 2020; 31732523, Klute et al., 2020; ASCO Abstract 122). </p> <p><b>Supporting Data:</b> One patient with BRAF V600E_positive NSCLC experienced a 15_month SD on vemurafenib plus cobimetinib after switching from dabrafenib plus trametinib due to toxicity (Chic et al., 2020; 32896487); a basket trial reported no responses for 2 patients with NSCLC (Meric_Bernstam et al., 2022; ASCO Abstract 3008). The combination of vemurafenib and cobimetinib has been reported to provide clinical benefit for patients with various solid tumors harboring BRAF alterations (Meric_Bernstam et al., 2022; ASCO Abstract 3008, Klute et al., 2020; ASCO Abstract 122, Chic et al., 2020; 32896487, Guidry et al., 2020; 33015265). The Phase 2 TAPUR basket study reported an ORR of 57% (2 CRs, 14 PRs, n=28), median PFS of 5.8 months, and median OS of 15.2 months for patients with BRAF mutations in various non_melanoma solid tumors, including 1 PR for a patient with an unspecified malignant neoplasm. Vemurafenib with cobimetinib has been studied primarily in the context of BRAF V600_mutated melanoma, where patients treated with this combination achieved greater PFS and OS compared with vemurafenib alone (Larkin et al., 2015; ASCO Abstract 9006, Ascierto et al., 2016; 27480103, Ribas et al., 2020; 31732523). Vemurafenib can induce adverse effects, such as the development of cutaneous squamous cell carcinomas, keratoacanthomas, and new primary melanomas caused by inactivation of wildtype BRAF and leading to paradoxical activation of the MAPK pathway (Gibney et al., 2013; 23712190, McArthur et al., 2014; 24508103). In a Phase 1b trial, patients with BRAF V600E_mutated melanoma treated with a combination of vemurafenib and cobimetinib had increased RR (87%) and PFS (13.7 months) compared to the RR and PFS values previously reported for vemurafenib or MEK inhibitor monotherapy; this combination also resulted in lower rates of cutaneous SCC (Ribas et al., 2014; 25037139). </p>", "ApprovedUses": null, "Effect": "Sensitizing", "Include": "true", "IncludeInSummary": "true", "ReferenceLinks": null}]}, "ReferenceLinks": null, "ClinicalTrialLinks": {"ClinicalTrialLink": [{"nctId": "NCT03178552", "Include": "true"}, {"nctId": "NCT03337698", "Include": "true"}, {"nctId": "NCT04585815", "Include": "true"}, {"nctId": "NCT04913285", "Include": "true"}, {"nctId": "NCT04452877", "Include": "true"}, {"nctId": "NCT03239015", "Include": "true"}, {"nctId": "NCT03781219", "Include": "true"}, {"nctId": "NCT04803318", "Include": "true"}, {"nctId": "NCT03284502", "Include": "true"}, {"nctId": "NCT04801966", "Include": "true"}]}}}, "ReferenceLinks": null}, {"Name": "Microsatellite status", "Include": "true", "Alterations": {"Alteration": {"Name": "MS_Stable", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "MS_Stable"}}, "Interpretation": "Microsatellite instability (MSI) is a condition of genetic hypermutability that generates excessive amounts of short insertion/deletion mutations in the genome; it generally occurs at microsatellite DNA sequences and is caused by a deficiency in DNA mismatch repair (MMR) in the tumor (Kocarnik et al., 2015; 26337942). Defective MMR and consequent MSI occur as a result of genetic or epigenetic inactivation of one of the MMR pathway proteins, primarily MLH1, MSH2, MSH6, or PMS2 (You et al., 2010; 21081928, Bairwa et al., 2014; 24623249, Kocarnik et al., 2015; 26337942). This sample is microsatellite_stable (MSS), equivalent to the clinical definition of an MSS tumor: one with mutations in none of the tested microsatellite markers (Boland et al., 1998; 9823339, Pawlik et al., 2004; 15528785, Boland and Goel, 2010; 20420947). MSS status indicates MMR proficiency and typically correlates with intact expression of all MMR family proteins (Kocarnik et al., 2015; 26337942, Bairwa et al., 2014; 24623249, Pawlik et al., 2004; 15528785, Boland and Goel, 2010; 20420947). MSI_H is generally infrequent in NSCLC, reported in fewer than 1% of samples across several large studies (Warth et al., 2016; 26637197, Ninomiya et al., 2006; 16641899, Vanderwalde et al., 2018; 29436178, Zang et al., 2019; 31270941, Dudley et al., 2016; 26880610, Takamochi et al., 2017; 28676214, Schrock et al., 2017; https://doi.org/10.1016/j.jtho.2016.11.487), whereas data on the reported incidence of MSI_H in SCLC has been limited and conflicting (Pylkkanen et al., 1997; 9329646, Gonzalez et al., 2000; 11061602, Chen et al., 1996; 8782463, Merlo et al., 1994; 8174113). One study reported MSI_H in lung adenocarcinoma patients with smoking history, and 3 of 4 MSI_H patients examined also had metachronous carcinomas in other organs, although this has not been investigated in large scale studies (Warth et al., 2016; 26637197). Published data investigating the prognostic implications of MSI in NSCLC are limited (PubMed, Oct 2022). On the basis of clinical evidence, MSS tumors are significantly less likely than MSI_H tumors to respond to anti_PD_1 immune checkpoint inhibitors (Gatalica et al., 2014; 25392179, Kroemer et al., 2015; 26140250, Lal et al., 2015; 25949894), including approved therapies nivolumab and pembrolizumab (Overman et al., 2016; ASCO Abstract 3501, Le et al., 2015; 26028255). In a retrospective analysis of 361 patients with solid tumors treated with pembrolizumab, 3% were MSI_H and experienced a significantly higher ORR compared with non_MSI_H cases (70% vs. 12%, p=0.001) (Ayers et al., 2016; ASCO_SITC Abstract P60).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "SETD2", "Include": "true", "Alterations": {"Alteration": {"Name": "D995fs*1", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "D995fs*1"}}, "Interpretation": "SETD2 encodes a histone lysine_36 methyltransferase (Sun et al., 2005; 16118227) that preferentially interacts with the expanded N_terminal polyglutamine tracts present in mutant huntingtin, implicating it in the pathogenesis of Huntington disease (Faber et al., 1998; 9700202). SETD2 mRNA expression has been observed to be consistently reduced in breast tumors relative to adjacent non_tumor tissue, suggesting a potential tumor suppressor role (Al Sarakbi et al., 2009; 19698110). SETD2 alterations such as observed here have been shown to be inactivating (Parker et al., 2016; 27282254, Zhang et al., 2012; 22237106, McKinney et al., 2017; 28122867, Moffitt et al., 2017; 28424246, Zhu et al., 2014; 24509477, Lu et al., 2016; 27174990). Somatic inactivating alterations of SETD2 are documented to occur at low frequency in a number of solid tumors, most commonly in renal carcinoma (Varela et al., 2011; 21248752). SETD2 has been associated with favorable prognosis in gastric cancer (Chen et al., 2018; 29522714). SETD2 has also been associated with poor prognosis in RCC and MDS (Chen et al., 2020; 32202636, Liu et al., 2015; 26559293), while data in other tumor types is limited (PubMed, Jun 2022). There are no targeted therapies available to address genomic alterations in SETD2.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "Tumor Mutation Burden", "Include": "true", "Alterations": {"Alteration": {"Name": "02", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "02"}}, "Interpretation": "Tumor mutation burden (TMB, also known as mutation load) is a measure of the number of somatic protein_coding base substitution and insertion/deletion mutations occurring in a tumor specimen. TMB is affected by a variety of causes, including exposure to mutagens such as ultraviolet light in melanoma (Pfeifer et al., 2005; 15748635, Hill et al., 2013; 23875803) and cigarette smoke in lung cancer (Pfeifer et al., 2002; 12379884, Rizvi et al., 2015; 25765070), treatment with temozolomide_based chemotherapy in glioma (Johnson et al., 2014; 24336570, Choi et al., 2018; 29452419), mutations in the proofreading domains of DNA polymerases encoded by the POLE and POLD1 genes (Cancer Genome Atlas Research Network, 2013; 23636398, Briggs and Tomlinson, 2013; 23447401, Heitzer and Tomlinson, 2014; 24583393, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919), and microsatellite instability (MSI) (Cancer Genome Atlas Research Network, 2013; 23636398, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919). This sample harbors a TMB below levels that would be predicted to be associated with sensitivity to PD_1_ or PD_L1_targeting immune checkpoint inhibitors, alone or in combination with other agents (Spigel et al., 2016; ASCO Abstract 9017, Hellmann et al., 2018; AACR Abstract CT077, Ramalingam et al., 2018; AACR Abstract CT078, Kowanetz et al., 2016; ESMO Abstract 77P, Gandara et al., 2017; ESMO Abstract 12950, Legrand et al., 2018; ASCO Abstract 12000, Velcheti et al., 2018; ASCO Abstract 12001, Herbst et al., 2019; ESMO Abstract LBA79, Peters et al., 2019; AACR Abstract CT07, Castellanos et al., 2019; ASCO Abstract 2630, Rizvi et al., 2015; 25765070, Colli et al., 2016; 27197178, Goodman et al., 2017; 28835386, Wang et al., 2017; 28923100, Carbone et al., 2017; 28636851, Rizvi et al., 2018; 29337640, Hellmann et al., 2018; 29658845, Hellmann et al., 2018; 29657128, Forde et al., 2018; 29658848, Ready et al., 2019; 30785829, Samstein et al., 2019; 30643254, Miao et al., 2018; 30150660, Chae et al., 2019; 30425022, Marabelle et al., 2020; 32919526). A large_scale genomic analysis found that unspecified lung non_small cell lung carcinoma (NSCLC), lung adenocarcinoma, and lung squamous cell carcinoma (SCC) samples harbored median TMBs between 6.3 and 9 Muts/Mb, and 12% to 17% of cases had an elevated TMB of greater than 20 Muts/Mb (FMI_Chalmers et al., 2017; 28420421). Lower TMB is observed more commonly in NSCLCs harboring known driver mutations (EGFR, ALK, ROS1, or MET) with the exception of BRAF or KRAS mutations, which are commonly observed in elevated TMB cases (Spigel et al., 2016; ASCO Abstract 9017). Although some studies have reported a lack of association between smoking and mutational burden in NSCLC (Schwartz et al., 2016; ASCO Abstract 8533, Xiao et al., 2016; 27009843, Shim et al., 2015; 26200269), several other large studies did find a strong association with increased TMB (Govindan et al., 2012; 22980976, Ding et al., 2008; 18948947, Imielinski et al., 2012; 22980975, Kim et al., 2014; 24323028). TMB >10 muts/Mb was found to be more frequent in NSCLC metastases compared with primary tumors for both adenocarcinoma (38% vs. 25%) and SCC (41% vs. 35%) subtypes (Stein et al., 2019; DOI: 10.1200/PO.18.00376). A meta_analysis of 19 studies of immune checkpoint inhibitor_treated NSCLC (n = 2,315 patients) demonstrated that high TMB predicted a significantly longer OS than low TMB (HR = 0.70), and within the high TMB group, immunotherapy was associated with an improved PFS (HR = 0.62, P<0.001), OS (HR = 0.67, P<0.001) and a higher response rate (OR = 2.35, P<0.001) compared to chemotherapy (Meng et al., 2022; 35113949). In contrast, a large study of Chinese patients with untreated lung adenocarcinoma reported a shorter median OS for tumors with a higher number of mutations in a limited gene set compared with a lower mutation number (48.4 vs. 61.0 months)(Xiao et al., 2016; 27009843). Another study of patients with NSCLC treated with EGFR inhibitors or platinum doublet chemotherapy found elevated TMB to be correlated with poorer prognosis, as well as finding lower TMB in combination with PD_L1 negative status to be significantly associated with longer median survival in patients with lung adenocarcinoma (Chen et al., 2019; 31088500). However, no significant prognostic association of TMB and/or PD_L1 status with survival has been reported in patients with lung SCC (Yu et al., 2019; 30253973, Chen et al., 2019; 31088500). On the basis of clinical evidence in solid tumors, increased TMB may be associated with greater sensitivity to immunotherapeutic agents, including anti_PD_L1 (Legrand et al., 2018; ASCO Abstract 12000, Samstein et al., 2019; 30643254, Goodman et al., 2017; 28835386, Goodman et al., 2019; 31405947), anti_PD_1 therapies (Cristescu et al., 2018; 30309915, Goodman et al., 2017; 28835386, Samstein et al., 2019; 30643254, Marabelle et al., 2019; ESMO Abstract 11920, Goodman et al., 2019; 31405947), and combination nivolumab and ipilimumab (Ready et al., 2019; 30785829, Hellmann et al., 2018; 29658845, Hellmann et al., 2018; 29657128, Rizvi et al., 2017; WCLC Abstract 1106, Hellmann et al., 2018; 29731394, Rozeman et al., 2021; 33558721, Hodi et al., 2019; AACR abstract CT037, Lee et al., 2019; ASCO Abstract 641, Sharma et al., 2020; 32916128). Multiple clinical trials of PD_1_ or PD_L1_targeting immune checkpoint inhibitors or combination of PD_1 and CTLA_4 inhibitors in NSCLC have reported that patients with tumors harboring TMB \u226510 Muts/Mb derive greater clinical benefit from these therapies than those with TMB <10 Muts/Mb (based on this assay or others); similarly, higher efficacy of anti_PD_1 or anti_PD_L1 immunotherapy for treatment of patients with NSCLC, compared with the use of chemotherapy, has been observed more significantly in cases of TMB \u226510 Muts/Mb (based on this assay or others); (Spigel et al., 2016; ASCO Abstract 9017, Hellmann et al., 2018; AACR Abstract CT077, Ramalingam et al., 2018; AACR Abstract CT078, Kowanetz et al., 2016; ESMO Abstract 77P, Gandara et al., 2017; ESMO Abstract 12950, Legrand et al., 2018; ASCO Abstract 12000, Velcheti et al., 2018; ASCO Abstract 12001, Herbst et al., 2019; ESMO Abstract LBA79, Peters et al., 2019; AACR Abstract CT07, Castellanos et al., 2019; ASCO Abstract 2630, Rizvi et al., 2015; 25765070, Colli et al., 2016; 27197178, Goodman et al., 2017; 28835386, Wang et al., 2017; 28923100, Carbone et al., 2017; 28636851, Rizvi et al., 2018; 29337640, Hellmann et al., 2018; 29658845, Hellmann et al., 2018; 29657128, Forde et al., 2018; 29658848, Ready et al., 2019; 30785829, Samstein et al., 2019; 30643254, Miao et al., 2018; 30150660, Chae et al., 2019; 30425022). Improved OS of patients with NSCLC treated with pembrolizumab plus chemotherapy relative to chemotherapy only (Paz_Ares et al., 2019; ESMO Abstract LBA80), or those treated with nivolumab plus ipilimumab also relative to chemotherapy (Hellmann et al., 2019; 31562796), has been observed across all TMB levels.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}]}, "Trials": {"Trial": [{"Gene": "BRAF", "Alteration": "V600E", "Title": "A Study to Evaluate Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non_Small Cell Lung Cancer (NSCLC)", "StudyPhase": "PHASE 2/3", "Target": "MEK, PD_L1, BRAF, KRAS", "Locations": "Taipei (Taiwan), Taoyuan (Taiwan), Kaohsiung (Taiwan), Shatin (Hong Kong), Seoul (Korea, Republic of), Goyang_si (Korea, Republic of), Bangkok (Thailand), Hat Yai (Thailand), Singapore (Singapore), St Leonards (Australia)", "NCTID": "NCT03178552", "Note": "BRAF V600 mutation may predict sensitivity to inhibitors of BRAF, MEK, or ERK. BRAF activating alterations may predict sensitivity to inhibitors of BRAF, MEK, or ERK. Limited clinical and preclinical studies indicate BRAF mutations may predict sensitivity to MEK_pan_RAF dual inhibitors.", "Include": "true"}, {"Gene": "BRAF", "Alteration": "V600E", "Title": "A Study Of Multiple Immunotherapy_Based Treatment Combinations In Participants With Metastatic Non_Small Cell Lung Cancer (Morpheus_ Non_Small Cell Lung Cancer)", "StudyPhase": "PHASE 1/2", "Target": "PD_L1, MEK, CEA, CXCR4, EZH2, MDM2, ADORA2A", "Locations": "Taipei City (Taiwan), Seoul (Korea, Republic of), Blacktown (Australia), Haifa (Israel), Petach Tikva (Israel), Ramat Gan (Israel), Newcastle upon Tyne (United Kingdom), Dijon (France), London (United Kingdom), Sutton (United Kingdom)", "NCTID": "NCT03337698", "Note": "BRAF V600 mutation may predict sensitivity to inhibitors of BRAF, MEK, or ERK. BRAF activating alterations may predict sensitivity to inhibitors of BRAF, MEK, or ERK. Limited clinical and preclinical studies indicate BRAF mutations may predict sensitivity to MEK_pan_RAF dual inhibitors.", "Include": "true"}, {"Gene": "BRAF", "Alteration": "V600E", "Title": "Umbrella Study of Sasanlimab Combined With Targeted Therapies in Participants With Non Small Cell Lung Cancer", "StudyPhase": "PHASE 1/2", "Target": "VEGFRs, PD_1, TIGIT, BRAF, MEK", "Locations": "Taipei (Taiwan), Taipei City (Taiwan), Taichung (Taiwan), Concord (Australia), St Leonards (Australia), Camperdown (Australia), Heidelberg (Australia), Edegem (Belgium), Newcastle upon Tyne (United Kingdom), London (United Kingdom)", "NCTID": "NCT04585815", "Note": "BRAF V600 mutation may predict sensitivity to inhibitors of BRAF, MEK, or ERK. BRAF activating alterations may predict sensitivity to inhibitors of BRAF, MEK, or ERK. Limited clinical and preclinical studies indicate BRAF mutations may predict sensitivity to MEK_pan_RAF dual inhibitors.", "Include": "true"}, {"Gene": "BRAF", "Alteration": "V600E", "Title": "A Study to Evaluate KIN_2787 in Subjects With BRAF Mutation Positive Solid Tumors", "StudyPhase": "PHASE 1", "Target": "BRAF, MEK", "Locations": "Taipei (Taiwan), Perth (Australia), Villejuif (France), Lyon (France), Nantes (France), Bordeaux (France), Barcelona (Spain), California, Valencia (Spain)", "NCTID": "NCT04913285", "Note": "BRAF V600 mutation may predict sensitivity to inhibitors of BRAF, MEK, or ERK. BRAF activating alterations may predict sensitivity to inhibitors of BRAF, MEK, or ERK. Limited clinical and preclinical studies indicate BRAF mutations may predict sensitivity to MEK_pan_RAF dual inhibitors.", "Include": "true"}, {"Gene": "BRAF", "Alteration": "V600E", "Title": "A Study of Dabrafenib in Combination With Trametinib in Chinese Patients With BRAF V600E Mutant Metastatic NSCLC", "StudyPhase": "PHASE 2", "Target": "BRAF, MEK", "Locations": "Hangzhou (China), Shanghai (China), Guangzhou (China), Changsha (China), Tianjin (China), Beijing (China), Chengdu (China), Harbin (China)", "NCTID": "NCT04452877", "Note": "BRAF V600 mutation may predict sensitivity to inhibitors of BRAF, MEK, or ERK. BRAF activating alterations may predict sensitivity to inhibitors of BRAF, MEK, or ERK. Limited clinical and preclinical studies indicate BRAF mutations may predict sensitivity to MEK_pan_RAF dual inhibitors.", "Include": "true"}, {"Gene": "BRAF", "Alteration": "V600E", "Title": "Efficacy and Safety of Targeted Precision Therapy in Refractory Tumor With Druggable Molecular Event", "StudyPhase": "PHASE 2", "Target": "EGFR, ERBB4, ERBB2, PARP, mTOR, MET, ROS1, RET, VEGFRs, BRAF, CDK4, CDK6", "Locations": "Shanghai (China)", "NCTID": "NCT03239015", "Note": "BRAF V600 mutation may predict sensitivity to inhibitors of BRAF, MEK, or ERK. BRAF activating alterations may predict sensitivity to inhibitors of BRAF, MEK, or ERK. Limited clinical and preclinical studies indicate BRAF mutations may predict sensitivity to MEK_pan_RAF dual inhibitors.", "Include": "true"}, {"Gene": "BRAF", "Alteration": "V600E", "Title": "A PhaseI Study of HL_085 Plus Vemurafenib in Solid Tumor With BRAF V600 Mutation", "StudyPhase": "PHASE 1", "Target": "MEK, BRAF", "Locations": "Hangzhou (China), Zhengzhou (China), Beijing (China)", "NCTID": "NCT03781219", "Note": "BRAF V600 mutation may predict sensitivity to inhibitors of BRAF, MEK, or ERK. BRAF activating alterations may predict sensitivity to inhibitors of BRAF, MEK, or ERK. Limited clinical and preclinical studies indicate BRAF mutations may predict sensitivity to MEK_pan_RAF dual inhibitors.", "Include": "true"}, {"Gene": "BRAF", "Alteration": "V600E", "Title": "Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors", "StudyPhase": "PHASE 2", "Target": "mTOR, FGFRs, RET, PDGFRA, VEGFRs, KIT, MEK", "Locations": "Guangzhou (China)", "NCTID": "NCT04803318", "Note": "BRAF V600 mutation may predict sensitivity to inhibitors of BRAF, MEK, or ERK. BRAF activating alterations may predict sensitivity to inhibitors of BRAF, MEK, or ERK. Limited clinical and preclinical studies indicate BRAF mutations may predict sensitivity to MEK_pan_RAF dual inhibitors.", "Include": "true"}, {"Gene": "BRAF", "Alteration": "V600E", "Title": "Cobimetinib and HM95573 in Patients With Locally Advanced or Metastatic Solid Tumors", "StudyPhase": "PHASE 1", "Target": "MEK, RAFs", "Locations": "Hwasun (Korea, Republic of), Pusan (Korea, Republic of), Seongnam (Korea, Republic of), Seoul (Korea, Republic of), Goyang_si (Korea, Republic of)", "NCTID": "NCT03284502", "Note": "BRAF V600 mutation may predict sensitivity to inhibitors of BRAF, MEK, or ERK. BRAF activating alterations may predict sensitivity to inhibitors of BRAF, MEK, or ERK. Limited clinical and preclinical studies indicate BRAF mutations may predict sensitivity to MEK_pan_RAF dual inhibitors.", "Include": "true"}, {"Gene": "BRAF", "Alteration": "V600E", "Title": "Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study", "StudyPhase": "PHASE null", "Target": "CDK4, CDK6, PI3K_alpha, PD_L1, MEK, PARP, PD_1, BRAF", "Locations": "Melbourne (Australia)", "NCTID": "NCT04801966", "Note": "BRAF V600 mutation may predict sensitivity to inhibitors of BRAF, MEK, or ERK. BRAF activating alterations may predict sensitivity to inhibitors of BRAF, MEK, or ERK. Limited clinical and preclinical studies indicate BRAF mutations may predict sensitivity to MEK_pan_RAF dual inhibitors.", "Include": "true"}]}, "References": {"Reference": [{"number": "0", "ReferenceId": "24957944", "FullCitation": "Holderfield M, et al. Nat. Rev. Cancer (2014) pmid: 24957944", "Include": "true"}, {"number": "1", "ReferenceId": "24948110", "FullCitation": "Burotto M, et al. Cancer (2014) pmid: 24948110", "Include": "true"}, {"number": "2", "ReferenceId": "12068308", "FullCitation": "Davies H, et al. Nature (2002) pmid: 12068308", "Include": "true"}, {"number": "3", "ReferenceId": "24132290", "FullCitation": "Kandoth C, et al. Nature (2013) pmid: 24132290", "Include": "true"}, {"number": "4", "ReferenceId": "23273605", "FullCitation": "Greaves WO, et al. J Mol Diagn (2013) pmid: 23273605", "Include": "true"}, {"number": "5", "ReferenceId": "23237741", "FullCitation": "Klein O, et al. Eur. J. Cancer (2013) pmid: 23237741", "Include": "true"}, {"number": "6", "ReferenceId": "15059882", "FullCitation": "Wellbrock C, et al. Cancer Res. (2004) pmid: 15059882", "Include": "true"}, {"number": "7", "ReferenceId": "22735384", "FullCitation": "Hauschild A, et al. Lancet (2012) pmid: 22735384", "Include": "true"}, {"number": "8", "ReferenceId": "24508103", "FullCitation": "McArthur GA, et al. Lancet Oncol. (2014) pmid: 24508103", "Include": "true"}, {"number": "9", "ReferenceId": "22904646", "FullCitation": "Fisher R, et al. Cancer Manag Res (2012) pmid: 22904646", "Include": "true"}, {"number": "10", "ReferenceId": "20551065", "FullCitation": "Yang H, et al. Cancer Res. (2010) pmid: 20551065", "Include": "true"}, {"number": "11", "ReferenceId": "23317446", "FullCitation": "Gentilcore G, et al. BMC Cancer (2013) pmid: 23317446", "Include": "true"}, {"number": "12", "ReferenceId": "23473613", "FullCitation": "van den Brom RR, et al. Eur. J. Cancer (2013) pmid: 23473613", "Include": "true"}, {"number": "13", "ReferenceId": "23490649", "FullCitation": "Klein O, et al. Eur. J. Cancer (2013) pmid: 23490649", "Include": "true"}, {"number": "14", "ReferenceId": "23463675", "FullCitation": "Ponti G, et al. J. Clin. Pathol. (2013) pmid: 23463675", "Include": "true"}, {"number": "15", "ReferenceId": "23031422", "FullCitation": "Ponti G, et al. J Hematol Oncol (2012) pmid: 23031422", "Include": "true"}, {"number": "16", "ReferenceId": "25382067", "FullCitation": "Parakh S, et al. J Clin Pharm Ther (2015) pmid: 25382067", "Include": "true"}, {"number": "17", "ReferenceId": "28194436", "FullCitation": "Lee LH, et al. JCI Insight (2017) pmid: 28194436", "Include": "true"}, {"number": "18", "ReferenceId": "21483012", "FullCitation": "Paik PK, et al. J. Clin. Oncol. (2011) pmid: 21483012", "Include": "true"}, {"number": "19", "ReferenceId": "24552757", "FullCitation": "Brustugun OT, et al. Lung Cancer (2014) pmid: 24552757", "Include": "true"}, {"number": "20", "ReferenceId": "24594201", "FullCitation": "Carneiro JG, et al. Genet Res (Camb) (2014) pmid: 24594201", "Include": "true"}, {"number": "21", "ReferenceId": "24743704", "FullCitation": "Li S, et al. Br. J. Cancer (2014) pmid: 24743704", "Include": "true"}, {"number": "22", "ReferenceId": "24979348", "FullCitation": "Chen D, et al. PLoS ONE (2014) pmid: 24979348", "Include": "true"}, {"number": "23", "ReferenceId": "33872981", "FullCitation": "Wiesweg M, et al. Eur J Cancer (2021) pmid: 33872981", "Include": "true"}, {"number": "24", "ReferenceId": "31181537", "FullCitation": "Couraud S, et al. Eur J Cancer (2019) pmid: 31181537", "Include": "true"}, {"number": "25", "ReferenceId": "30224342", "FullCitation": "Dagogo_Jack I, et al. Clin Cancer Res (2019) pmid: 30224342", "Include": "true"}, {"number": "26", "ReferenceId": "31470866", "FullCitation": "Lin Q, et al. J Transl Med (2019) pmid: 31470866", "Include": "true"}, {"number": "27", "ReferenceId": "31125062", "FullCitation": "Mazieres J, et al. Ann Oncol (2019) pmid: 31125062", "Include": "true"}, {"number": "28", "ReferenceId": "28919011", "FullCitation": "Planchard D, et al. Lancet Oncol. (2017) pmid: 28919011", "Include": "true"}, {"number": "29", "ReferenceId": "27283860", "FullCitation": "Planchard D, et al. Lancet Oncol. (2016) pmid: 27283860", "Include": "true"}, {"number": "30", "ReferenceId": "31959346", "FullCitation": "Mazieres J, et al. Ann. Oncol. (2020) pmid: 31959346", "Include": "true"}, {"number": "31", "ReferenceId": "32029534", "FullCitation": "Subbiah V, et al. Cancer Discov (2020) pmid: 32029534", "Include": "true"}, {"number": "32", "ReferenceId": "29320312", "FullCitation": "Hainsworth JD, et al. J. Clin. Oncol. (2018) pmid: 29320312", "Include": "true"}, {"number": "33", "ReferenceId": "27080216", "FullCitation": "Planchard D, et al. Lancet Oncol. (2016) pmid: 27080216", "Include": "true"}, {"number": "34", "ReferenceId": "29247021", "FullCitation": "Sullivan RJ, et al. Cancer Discov (2018) pmid: 29247021", "Include": "true"}, {"number": "35", "ReferenceId": "22761467", "FullCitation": "Martinez_Garcia M, et al. Clin. Cancer Res. (2012) pmid: 22761467", "Include": "true"}, {"number": "36", "ReferenceId": "33128873", "FullCitation": "Guo C, et al. Lancet Oncol (2020) pmid: 33128873", "Include": "true"}, {"number": "37", "ReferenceId": "26337942", "FullCitation": "Kocarnik JM, et al. Gastroenterol Rep (Oxf) (2015) pmid: 26337942", "Include": "true"}, {"number": "38", "ReferenceId": "21081928", "FullCitation": "You JF, et al. Br. J. Cancer (2010) pmid: 21081928", "Include": "true"}, {"number": "39", "ReferenceId": "24623249", "FullCitation": "Bairwa NK, et al. Methods Mol. Biol. (2014) pmid: 24623249", "Include": "true"}, {"number": "40", "ReferenceId": "9823339", "FullCitation": "Boland CR, et al. Cancer Res. (1998) pmid: 9823339", "Include": "true"}, {"number": "41", "ReferenceId": "15528785", "FullCitation": "Pawlik TM, et al. Dis. Markers (2004) pmid: 15528785", "Include": "true"}, {"number": "42", "ReferenceId": "20420947", "FullCitation": "Boland CR, et al. Gastroenterology (2010) pmid: 20420947", "Include": "true"}, {"number": "43", "ReferenceId": "26637197", "FullCitation": "Warth A, et al. Virchows Arch. (2016) pmid: 26637197", "Include": "true"}, {"number": "44", "ReferenceId": "16641899", "FullCitation": "Ninomiya H, et al. Br. J. Cancer (2006) pmid: 16641899", "Include": "true"}, {"number": "45", "ReferenceId": "29436178", "FullCitation": "Vanderwalde A, et al. Cancer Med (2018) pmid: 29436178", "Include": "true"}, {"number": "46", "ReferenceId": "31270941", "FullCitation": "Zang YS, et al. Cancer Med (2019) pmid: 31270941", "Include": "true"}, {"number": "47", "ReferenceId": "26880610", "FullCitation": "Dudley JC, et al. Clin. Cancer Res. (2016) pmid: 26880610", "Include": "true"}, {"number": "48", "ReferenceId": "28676214", "FullCitation": "Takamochi K, et al. Lung Cancer (2017) pmid: 28676214", "Include": "true"}, {"number": "49", "ReferenceId": "9329646", "FullCitation": "Pylkk\u00e4nen L, et al. Environ. Mol. Mutagen. (1997) pmid: 9329646", "Include": "true"}, {"number": "50", "ReferenceId": "11061602", "FullCitation": "Gonzalez R, et al. Ann. Oncol. (2000) pmid: 11061602", "Include": "true"}, {"number": "51", "ReferenceId": "8782463", "FullCitation": "Chen XQ, et al. Nat. Med. (1996) pmid: 8782463", "Include": "true"}, {"number": "52", "ReferenceId": "8174113", "FullCitation": "Merlo A, et al. Cancer Res. (1994) pmid: 8174113", "Include": "true"}, {"number": "53", "ReferenceId": "25392179", "FullCitation": "Gatalica Z, et al. Cancer Epidemiol. Biomarkers Prev. (2014) pmid: 25392179", "Include": "true"}, {"number": "54", "ReferenceId": "26140250", "FullCitation": "Kroemer G, et al. Oncoimmunology (2015) pmid: 26140250", "Include": "true"}, {"number": "55", "ReferenceId": "25949894", "FullCitation": "Lal N, et al. Oncoimmunology (2015) pmid: 25949894", "Include": "true"}, {"number": "56", "ReferenceId": "26028255", "FullCitation": "Le DT, et al. N. Engl. J. Med. (2015) pmid: 26028255", "Include": "true"}, {"number": "57", "ReferenceId": "16118227", "FullCitation": "Sun XJ, et al. J. Biol. Chem. (2005) pmid: 16118227", "Include": "true"}, {"number": "58", "ReferenceId": "9700202", "FullCitation": "Faber PW, et al. Hum. Mol. Genet. (1998) pmid: 9700202", "Include": "true"}, {"number": "59", "ReferenceId": "19698110", "FullCitation": "Al Sarakbi W, et al. BMC Cancer (2009) pmid: 19698110", "Include": "true"}, {"number": "60", "ReferenceId": "27282254", "FullCitation": "Parker H, et al. Leukemia (2016) pmid: 27282254", "Include": "true"}, {"number": "61", "ReferenceId": "22237106", "FullCitation": "Zhang J, et al. Nature (2012) pmid: 22237106", "Include": "true"}, {"number": "62", "ReferenceId": "28122867", "FullCitation": "McKinney M, et al. Cancer Discov (2017) pmid: 28122867", "Include": "true"}, {"number": "63", "ReferenceId": "28424246", "FullCitation": "Moffitt AB, et al. J. Exp. Med. (2017) pmid: 28424246", "Include": "true"}, {"number": "64", "ReferenceId": "24509477", "FullCitation": "Zhu X, et al. Nat. Genet. (2014) pmid: 24509477", "Include": "true"}, {"number": "65", "ReferenceId": "27174990", "FullCitation": "Lu C, et al. Science (2016) pmid: 27174990", "Include": "true"}, {"number": "66", "ReferenceId": "21248752", "FullCitation": "Varela I, et al. Nature (2011) pmid: 21248752", "Include": "true"}, {"number": "67", "ReferenceId": "29522714", "FullCitation": "Chen Z, et al. Biochem Biophys Res Commun (2018) pmid: 29522714", "Include": "true"}, {"number": "68", "ReferenceId": "32202636", "FullCitation": "Chen BY, et al. Blood (2020) pmid: 32202636", "Include": "true"}, {"number": "69", "ReferenceId": "26559293", "FullCitation": "Liu W, et al. Medicine (Baltimore) (2015) pmid: 26559293", "Include": "true"}, {"number": "70", "ReferenceId": "15748635", "FullCitation": "Pfeifer GP, et al. Mutat. Res. (2005) pmid: 15748635", "Include": "true"}, {"number": "71", "ReferenceId": "23875803", "FullCitation": "Hill VK, et al. Annu Rev Genomics Hum Genet (2013) pmid: 23875803", "Include": "true"}, {"number": "72", "ReferenceId": "12379884", "FullCitation": "Pfeifer GP, et al. Oncogene (2002) pmid: 12379884", "Include": "true"}, {"number": "73", "ReferenceId": "25765070", "FullCitation": "Rizvi NA, et al. Science (2015) pmid: 25765070", "Include": "true"}, {"number": "74", "ReferenceId": "24336570", "FullCitation": "Johnson BE, et al. Science (2014) pmid: 24336570", "Include": "true"}, {"number": "75", "ReferenceId": "29452419", "FullCitation": "Choi S, et al. Neuro_oncology (2018) pmid: 29452419", "Include": "true"}, {"number": "76", "ReferenceId": "23636398", "FullCitation": "Cancer Genome Atlas Research Network, et al. Nature (2013) pmid: 23636398", "Include": "true"}, {"number": "77", "ReferenceId": "23447401", "FullCitation": "Briggs S, et al. J. Pathol. (2013) pmid: 23447401", "Include": "true"}, {"number": "78", "ReferenceId": "24583393", "FullCitation": "Heitzer E, et al. Curr. Opin. Genet. Dev. (2014) pmid: 24583393", "Include": "true"}, {"number": "79", "ReferenceId": "22810696", "FullCitation": "Nature (2012) pmid: 22810696", "Include": "true"}, {"number": "80", "ReferenceId": "25568919", "FullCitation": "Roberts SA, et al. Nat. Rev. Cancer (2014) pmid: 25568919", "Include": "true"}, {"number": "81", "ReferenceId": "27197178", "FullCitation": "Colli LM, et al. Cancer Res. (2016) pmid: 27197178", "Include": "true"}, {"number": "82", "ReferenceId": "28835386", "FullCitation": "Goodman AM, et al. Mol. Cancer Ther. (2017) pmid: 28835386", "Include": "true"}, {"number": "83", "ReferenceId": "28923100", "FullCitation": "Wang VE, et al. J Immunother Cancer (2017) pmid: 28923100", "Include": "true"}, {"number": "84", "ReferenceId": "28636851", "FullCitation": "Carbone DP, et al. N. Engl. J. Med. (2017) pmid: 28636851", "Include": "true"}, {"number": "85", "ReferenceId": "29337640", "FullCitation": "Rizvi H, et al. J. Clin. Oncol. (2018) pmid: 29337640", "Include": "true"}, {"number": "86", "ReferenceId": "29658845", "FullCitation": "Hellmann MD, et al. N. Engl. J. Med. (2018) pmid: 29658845", "Include": "true"}, {"number": "87", "ReferenceId": "29657128", "FullCitation": "Hellmann MD, et al. Cancer Cell (2018) pmid: 29657128", "Include": "true"}, {"number": "88", "ReferenceId": "29658848", "FullCitation": "Forde PM, et al. N. Engl. J. Med. (2018) pmid: 29658848", "Include": "true"}, {"number": "89", "ReferenceId": "30785829", "FullCitation": "Ready N, et al. J. Clin. Oncol. (2019) pmid: 30785829", "Include": "true"}, {"number": "90", "ReferenceId": "30643254", "FullCitation": "Samstein RM, et al. Nat. Genet. (2019) pmid: 30643254", "Include": "true"}, {"number": "91", "ReferenceId": "30150660", "FullCitation": "Miao D, et al. Nat. Genet. (2018) pmid: 30150660", "Include": "true"}, {"number": "92", "ReferenceId": "30425022", "FullCitation": "Chae YK, et al. Clin Lung Cancer (2019) pmid: 30425022", "Include": "true"}, {"number": "93", "ReferenceId": "32919526", "FullCitation": "Marabelle A, et al. Lancet Oncol. (2020) pmid: 32919526", "Include": "true"}, {"number": "94", "ReferenceId": "28420421", "FullCitation": "Chalmers ZR, et al. Genome Med (2017) pmid: 28420421", "Include": "true"}, {"number": "95", "ReferenceId": "27009843", "FullCitation": "Xiao D, et al. Oncotarget (2016) pmid: 27009843", "Include": "true"}, {"number": "96", "ReferenceId": "26200269", "FullCitation": "Shim HS, et al. J Thorac Oncol (2015) pmid: 26200269", "Include": "true"}, {"number": "97", "ReferenceId": "22980976", "FullCitation": "Govindan R, et al. Cell (2012) pmid: 22980976", "Include": "true"}, {"number": "98", "ReferenceId": "18948947", "FullCitation": "Ding L, et al. Nature (2008) pmid: 18948947", "Include": "true"}, {"number": "99", "ReferenceId": "22980975", "FullCitation": "Imielinski M, et al. Cell (2012) pmid: 22980975", "Include": "true"}, {"number": "100", "ReferenceId": "24323028", "FullCitation": "Kim Y, et al. J. Clin. Oncol. (2014) pmid: 24323028", "Include": "true"}, {"number": "101", "ReferenceId": "35113949", "FullCitation": "Meng G, et al. PLoS One (2022) pmid: 35113949", "Include": "true"}, {"number": "102", "ReferenceId": "31088500", "FullCitation": "Chen Y, et al. J. Exp. Clin. Cancer Res. (2019) pmid: 31088500", "Include": "true"}, {"number": "103", "ReferenceId": "30253973", "FullCitation": "Yu H, et al. J Thorac Oncol (2019) pmid: 30253973", "Include": "true"}, {"number": "104", "ReferenceId": "31405947", "FullCitation": "Goodman AM, et al. Cancer Immunol Res (2019) pmid: 31405947", "Include": "true"}, {"number": "105", "ReferenceId": "30309915", "FullCitation": "Cristescu R, et al. Science (2018) pmid: 30309915", "Include": "true"}, {"number": "106", "ReferenceId": "29731394", "FullCitation": "Hellmann MD, et al. Cancer Cell (2018) pmid: 29731394", "Include": "true"}, {"number": "107", "ReferenceId": "33558721", "FullCitation": "Rozeman EA, et al. Nat Med (2021) pmid: 33558721", "Include": "true"}, {"number": "108", "ReferenceId": "32916128", "FullCitation": "Sharma P, et al. Cancer Cell (2020) pmid: 32916128", "Include": "true"}, {"number": "109", "ReferenceId": "31562796", "FullCitation": "Hellmann MD, et al. N. Engl. J. Med. (2019) pmid: 31562796", "Include": "true"}, {"number": "110", "ReferenceId": "29573941", "FullCitation": "Dummer R, et al. Lancet Oncol. (2018) pmid: 29573941", "Include": "true"}, {"number": "111", "ReferenceId": "32669376", "FullCitation": "Sullivan RJ, et al. Clin Cancer Res (2020) pmid: 32669376", "Include": "true"}, {"number": "112", "ReferenceId": "31757377", "FullCitation": "McLoughlin EM, et al. J Thorac Oncol (2019) pmid: 31757377", "Include": "true"}, {"number": "113", "ReferenceId": "31901705", "FullCitation": "Ascierto PA, et al. Eur. J. Cancer (2020) pmid: 31901705", "Include": "true"}, {"number": "114", "ReferenceId": "31658370", "FullCitation": "Holbrook K, et al. Cancer (2020) pmid: 31658370", "Include": "true"}, {"number": "115", "ReferenceId": "23712190", "FullCitation": "Gibney GT, et al. Nat Rev Clin Oncol (2013) pmid: 23712190", "Include": "true"}, {"number": "116", "ReferenceId": "25285888", "FullCitation": "Falchook GS, et al. Thyroid (2015) pmid: 25285888", "Include": "true"}, {"number": "117", "ReferenceId": "23020132", "FullCitation": "Flaherty KT, et al. N. Engl. J. Med. (2012) pmid: 23020132", "Include": "true"}, {"number": "118", "ReferenceId": "25265492", "FullCitation": "Long GV, et al. N. Engl. J. Med. (2014) pmid: 25265492", "Include": "true"}, {"number": "119", "ReferenceId": "25185693", "FullCitation": "Peters S, et al. Melanoma Res. (2014) pmid: 25185693", "Include": "true"}, {"number": "120", "ReferenceId": "26037941", "FullCitation": "Long GV, et al. Lancet (2015) pmid: 26037941", "Include": "true"}, {"number": "121", "ReferenceId": "25399551", "FullCitation": "Robert C, et al. N. Engl. J. Med. (2015) pmid: 25399551", "Include": "true"}, {"number": "122", "ReferenceId": "27048246", "FullCitation": "Klempner SJ, et al. Cancer Discov (2016) pmid: 27048246", "Include": "true"}, {"number": "123", "ReferenceId": "26200454", "FullCitation": "Gautschi O, et al. J Thorac Oncol (2015) pmid: 26200454", "Include": "true"}, {"number": "124", "ReferenceId": "23524406", "FullCitation": "Rudin CM, et al. J Thorac Oncol (2013) pmid: 23524406", "Include": "true"}, {"number": "125", "ReferenceId": "25037139", "FullCitation": "Ribas A, et al. Lancet Oncol. (2014) pmid: 25037139", "Include": "true"}, {"number": "126", "ReferenceId": "32896487", "FullCitation": "Chic N, et al. Clin Lung Cancer (2020) pmid: 32896487", "Include": "true"}, {"number": "127", "ReferenceId": "33015265", "FullCitation": "Guidry J, et al. JAAD Case Rep (2020) pmid: 33015265", "Include": "true"}, {"number": "128", "ReferenceId": "27480103", "FullCitation": "Ascierto PA, et al. Lancet Oncol. (2016) pmid: 27480103", "Include": "true"}, {"number": "129", "ReferenceId": "31732523", "FullCitation": "Ribas A, et al. Clin. Cancer Res. (2020) pmid: 31732523", "Include": "true"}, {"number": "130", "ReferenceId": "34455067", "FullCitation": "Planchard D, et al. J Thorac Oncol (2022) pmid: 34455067", "Include": "true"}, {"number": "131", "ReferenceId": "33276639", "FullCitation": "Auliac JB, et al. Cancers (Basel) (2020) pmid: 33276639", "Include": "true"}, {"number": "132", "ReferenceId": "32411601", "FullCitation": "Mu Y, et al. Front Oncol (2020) pmid: 32411601", "Include": "true"}, {"number": "133", "ReferenceId": "33278771", "FullCitation": "Kashizaki F, et al. Eur J Cancer (2021) pmid: 33278771", "Include": "true"}, {"number": "134", "ReferenceId": "33215864", "FullCitation": "Dotsu Y, et al. Thorac Cancer (2021) pmid: 33215864", "Include": "true"}, {"number": "135", "ReferenceId": "32093631", "FullCitation": "Adachi Y, et al. BMC Cancer (2020) pmid: 32093631", "Include": "true"}, {"number": "136", "ReferenceId": "34023984", "FullCitation": "Shimada Y, et al. Invest New Drugs (2021) pmid: 34023984", "Include": "true"}, {"number": "137", "ReferenceId": "31250402", "FullCitation": "Clin Drug Investig (2019) pmid: 31250402", "Include": "true"}, {"number": "138", "ReferenceId": "34516041", "FullCitation": "Li J, et al. Oncologist (2021) pmid: 34516041", "Include": "true"}, {"number": "139", "ReferenceId": "34484797", "FullCitation": "Ota T, et al. Respirol Case Rep (2021) pmid: 34484797", "Include": "true"}, {"number": "140", "ReferenceId": "31027751", "FullCitation": "Yamamoto G, et al. J Thorac Oncol (2019) pmid: 31027751", "Include": "true"}, {"number": "141", "ReferenceId": "28024926", "FullCitation": "Pervere LM, et al. Clin Lung Cancer (2017) pmid: 28024926", "Include": "true"}, {"number": "142", "ReferenceId": "31440061", "FullCitation": "Kim HC, et al. Onco Targets Ther (2019) pmid: 31440061", "Include": "true"}, {"number": "143", "ReferenceId": "32522509", "FullCitation": "Tsakonas G, et al. Clin Lung Cancer (2020) pmid: 32522509", "Include": "true"}, {"number": "144", "ReferenceId": "34590045", "FullCitation": "Su PL, et al. JTO Clin Res Rep (2021) pmid: 34590045", "Include": "true"}, {"number": "145", "ReferenceId": "32981611", "FullCitation": "J Thorac Oncol (2020) pmid: 32981611", "Include": "true"}, {"number": "146", "ReferenceId": "32553555", "FullCitation": "Liu Y, et al. Lung Cancer (2020) pmid: 32553555", "Include": "true"}, {"number": "147", "ReferenceId": "28475671", "FullCitation": "Long GV, et al. Ann. Oncol. (2017) pmid: 28475671", "Include": "true"}, {"number": "148", "ReferenceId": "29072975", "FullCitation": "Subbiah V, et al. J. Clin. Oncol. (2018) pmid: 29072975", "Include": "true"}, {"number": "149", "ReferenceId": "26392102", "FullCitation": "Corcoran RB, et al. J. Clin. Oncol. (2015) pmid: 26392102", "Include": "true"}, {"number": "150", "ReferenceId": "32758030", "FullCitation": "Salama AKS, et al. J Clin Oncol (2020) pmid: 32758030", "Include": "true"}, {"number": "151", "ReferenceId": "34476331", "FullCitation": "Hendifar A, et al. JCO Precis Oncol (2021) pmid: 34476331", "Include": "true"}, {"number": "152", "ReferenceId": "34838156", "FullCitation": "Wen PY, et al. Lancet Oncol (2022) pmid: 34838156", "Include": "true"}, {"number": "153", "ReferenceId": "32818466", "FullCitation": "Subbiah V, et al. Lancet Oncol (2020) pmid: 32818466", "Include": "true"}, {"number": "154", "ReferenceId": "23733758", "FullCitation": "Peters S, et al. J. Clin. Oncol. (2013) pmid: 23733758", "Include": "true"}, {"number": "155", "ReferenceId": "30214735", "FullCitation": "Liu X, et al. Mol Clin Oncol (2018) pmid: 30214735", "Include": "true"}, {"number": "156", "ReferenceId": "24888229", "FullCitation": "Robinson SD, et al. Lung Cancer (2014) pmid: 24888229", "Include": "true"}, {"number": "157", "ReferenceId": "28315738", "FullCitation": "Schrock AB, et al. J Thorac Oncol (2017) pmid: 28315738", "Include": "true"}, {"number": "158", "ReferenceId": "21639808", "FullCitation": "Chapman PB, et al. N. Engl. J. Med. (2011) pmid: 21639808", "Include": "true"}, {"number": "159", "ReferenceId": "32067683", "FullCitation": "Kurzrock R, et al. Ann. Oncol. (2020) pmid: 32067683", "Include": "true"}, {"number": "160", "ReferenceId": "26287849", "FullCitation": "Hyman DM, et al. N. Engl. J. Med. (2015) pmid: 26287849", "Include": "true"}, {"number": "161", "ReferenceId": "30580112", "FullCitation": "Larkin J, et al. Eur. J. Cancer (2019) pmid: 30580112", "Include": "true"}, {"number": "162", "ReferenceId": "30351999", "FullCitation": "Kaley T, et al. J. Clin. Oncol. (2018) pmid: 30351999", "Include": "true"}]}, "Signatures": {"Signature": {"ServerTime": "2022_10_26 14:20:49", "OpName": "Erik Williams, M.D. | Julia Elvin, M.D., Ph.D., Laboratory Director", "Text": "Erik Williams, M.D. | Julia Elvin, M.D., Ph.D., Laboratory Director"}}, "reportProperties": {"reportProperty": [{"identifier": "QualityControlMetrics", "key": "MedianCoverageValue", "value": "844x"}, {"identifier": "AdditionalFindings", "key": "TumorMutationBurdenScore", "value": "2 Muts/Mb"}, {"identifier": "AdditionalFindings", "key": "MicrosatelliteStatusScore", "value": "0 fraction_unstable_loci"}, {"identifier": "AdditionalFindings", "key": "LossOfHeterozygosityScore", "value": "Units Not Reported"}, {"identifier": "AdditionalFindings", "key": "BloodTumorMutationalBurdenScore", "value": "Units Not Reported"}, {"identifier": "AdditionalFindings", "key": "TumorFractionScore", "value": "Units Not Reported"}]}, "comments": null, "AAC": {"Amendmends": null}}, "variant_report": {"xmlns": "http://foundationmedicine.com/compbio/variant_report_external", "disease": "LUNG", "disease_ontology": "Lung adenocarcinoma", "flowcell_analysis": "2000024137", "gender": "female", "pathology_diagnosis": "Lung Adenocarcinoma", "percent_tumor_nuclei": "30", "pipeline_version": "v3.14.1", "purity_assessment": "21.4", "specimen": "ORD_1479431_01*US1418085.01", "study": "CLINICAL_F1CDx v2", "test_request": "ORD_1479431_01", "test_type": "FoundationOneDx", "tissue_of_origin": "Lung", "xsischemaLocation": "http://foundationmedicine.com/compbio/variant_report_external http://integration.foundationmedicine.com/reporting/variant_report_external_2.2.xsd", "samples": {"sample": {"bait_set": "DX2", "mean_exon_depth": "845.16", "name": "SQ_US1418085.01_1", "nucleic_acid_type": "DNA"}}, "quality_control": {"status": "Pass"}, "short_variants": {"short_variant": [{"allele_fraction": "0.588", "cds_effect": "3035C>T", "depth": "415", "equivocal": "false", "functional_effect": "missense", "gene": "BRD4", "percent_reads": "58.8", "position": "chr19:15353845", "protein_effect": "P1012L", "status": "unknown", "strand": "_", "transcript": "NM_058243", "dna_evidence": {"sample": "SQ_US1418085.01_1"}}, {"allele_fraction": "0.1057", "cds_effect": "2468C>A", "depth": "861", "equivocal": "false", "functional_effect": "missense", "gene": "STAG2", "percent_reads": "10.57", "position": "chrX:123205108", "protein_effect": "S823Y", "status": "unknown", "strand": "+", "transcript": "NM_006603", "dna_evidence": {"sample": "SQ_US1418085.01_1"}}, {"allele_fraction": "0.1434", "cds_effect": "1799T>A", "depth": "802", "equivocal": "false", "functional_effect": "missense", "gene": "BRAF", "percent_reads": "14.34", "position": "chr7:140453136", "protein_effect": "V600E", "status": "known", "strand": "_", "transcript": "NM_004333", "dna_evidence": {"sample": "SQ_US1418085.01_1"}}, {"allele_fraction": "0.4696", "cds_effect": "1520A>T", "depth": "494", "equivocal": "false", "functional_effect": "missense", "gene": "MST1R", "percent_reads": "46.96", "position": "chr3:49936328", "protein_effect": "D507V", "status": "unknown", "strand": "_", "transcript": "NM_002447", "dna_evidence": {"sample": "SQ_US1418085.01_1"}}, {"allele_fraction": "0.2339", "cds_effect": "2982_2983insT", "depth": "949", "equivocal": "false", "functional_effect": "frameshift", "gene": "SETD2", "percent_reads": "23.39", "position": "chr3:47163143", "protein_effect": "D995fs*1", "status": "likely", "strand": "_", "transcript": "NM_014159", "dna_evidence": {"sample": "SQ_US1418085.01_1"}}, {"allele_fraction": "0.4834", "cds_effect": "463A>G", "depth": "722", "equivocal": "false", "functional_effect": "missense", "gene": "CIC", "percent_reads": "48.34", "position": "chr19:42791482", "protein_effect": "I155V", "status": "unknown", "strand": "+", "transcript": "NM_015125", "dna_evidence": {"sample": "SQ_US1418085.01_1"}}, {"allele_fraction": "0.4879", "cds_effect": "2386A>T", "depth": "990", "equivocal": "false", "functional_effect": "missense", "gene": "SPEN", "percent_reads": "48.79", "position": "chr1:16255121", "protein_effect": "T796S", "status": "unknown", "strand": "+", "transcript": "NM_015001", "dna_evidence": {"sample": "SQ_US1418085.01_1"}}, {"allele_fraction": "0.4653", "cds_effect": "3923G>T", "depth": "404", "equivocal": "false", "functional_effect": "missense", "gene": "IRS2", "percent_reads": "46.53", "position": "chr13:110434478", "protein_effect": "G1308V", "status": "unknown", "strand": "_", "transcript": "NM_003749", "dna_evidence": {"sample": "SQ_US1418085.01_1"}}, {"allele_fraction": "0.4444", "cds_effect": "104G>A", "depth": "513", "equivocal": "false", "functional_effect": "missense", "gene": "MKNK1", "percent_reads": "44.44", "position": "chr1:47048932", "protein_effect": "R35Q", "status": "unknown", "strand": "_", "transcript": "NM_003684", "dna_evidence": {"sample": "SQ_US1418085.01_1"}}]}, "copy_number_alterations": null, "rearrangements": null, "biomarkers": {"microsatellite_instability": {"status": "MSS"}, "tumor_mutation_burden": {"score": "2.41", "status": "low", "unit": "mutations_per_megabase"}}, "non_human_content": null}}}}